文献速递骨软组织肉瘤与黑色素瘤

艾日布林对比达卡巴嗪在晚期脂肪肉瘤中的疗效:III期随机研究亚组分析

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
PubMed 文献 · J Clin Oncol · 2017-08-30

该III期随机研究亚组分析纳入既往接受过含蒽环类方案治疗的晚期脂肪肉瘤患者,比较艾日布林与达卡巴嗪的疗效与安全性。结果显示艾日布林组总生存期显著优于达卡巴嗪组(15.6个月 vs 8.4个月,HR 0.51,95%CI 0.35-0.75,P<.001),无进展生存期亦显著改善(2.9个月 vs 1.7个月,HR 0.52,95%CI 0.35-0.78,P=.0015),两组不良事件相似。

要点

  • 艾日布林组中位OS 15.6个月,达卡巴嗪组8.4个月,HR 0.51(95%CI 0.35-0.75,P<.001)。
  • 艾日布林组中位PFS 2.9个月,达卡巴嗪组1.7个月,HR 0.52(95%CI 0.35-0.78,P=.0015)。
  • 各脂肪肉瘤组织学亚型及地理区域均观察到艾日布林组OS延长。

核心结论

  • 在既往治疗的晚期脂肪肉瘤患者中,艾日布林相比达卡巴嗪与显著更优的总生存期和无进展生存期相关。
  • 艾日布林是脂肪肉瘤的重要治疗选择,该亚型有效全身治疗有限。
  • 作者认为需进一步研究探索艾日布林用于更早线治疗及与其他药物联合的作用。

研究设计与样本

  • III期随机试验的脂肪肉瘤独立随机分层亚组分析,比较艾日布林与达卡巴嗪。
  • 纳入≥18岁、不可手术或放疗治愈的晚期或转移性去分化、黏液样/圆细胞或多形性脂肪肉瘤患者。
  • 患者ECOG体能状态≤2且既往接受≥2线全身治疗(包括1线含蒽环类方案),按1:1随机分组。
  • 艾日布林组接受甲磺酸艾日布林1.4 mg/m2静脉注射(第1天和第8天),达卡巴嗪组接受850、1000或1200 mg/m2静脉注射(第1天),每21天为一周期。

主要发现

  • 脂肪肉瘤亚组中,艾日布林组中位OS 15.6个月 vs 达卡巴嗪组8.4个月(HR 0.51,95%CI 0.35-0.75,P<.001)。
  • 艾日布林组中位PFS 2.9个月 vs 达卡巴嗪组1.7个月(HR 0.52,95%CI 0.35-0.78,P=.0015)。
  • 所有评估的脂肪肉瘤组织学亚型及地理区域中均观察到艾日布林组OS更长。
  • 两组不良事件相似。

关键数值与推荐

  • 脂肪肉瘤亚组OS:艾日布林组15.6个月 vs 达卡巴嗪组8.4个月,HR 0.51(95%CI 0.35-0.75,P<.001)。
  • 脂肪肉瘤亚组PFS:艾日布林组2.9个月 vs 达卡巴嗪组1.7个月,HR 0.52(95%CI 0.35-0.78,P=.0015)。

临床怎么用

  • 作者结论认为艾日布林是既往治疗晚期脂肪肉瘤患者的重要治疗选择。
  • 作者认为需进一步研究探索艾日布林用于更早线治疗及与其他药物联合的作用。
  • 原文未据此给出其他推荐。

局限性

  • 原文报告需进一步研究以探索艾日布林用于更早线治疗及与其他药物联合的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overall survival (OS) for the eribulin arm, with a manageable toxicity profile. We now report the histology-specific subgroup analysis of the efficacy and safety of eribulin compared with dacarbazine in patients with LPS, an independently randomized stratified subgroup of this phase III trial. Methods Patients ≥ 18 years with advanced or metastatic dedifferentiated, myxoid/round cell, or pleomorphic LPS incurable by surgery or radiotherapy were included. Patients with Eastern Cooperative Oncology Group performance status ≤ 2 and two or more prior systemic treatment regimens, including one with anthracycline, were randomly assigned 1:1 to receive eribulin mesylate (1.4 mg/m2 intravenously on days 1 and 8) or dacarbazine (850, 1,000, or 1,200 mg/m2 intravenously on day 1) every 21 days. OS, progression-free survival (PFS), and safety were analyzed. Results In the LPS subgroup, OS was significantly improved: 15.6 versus 8.4 months (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P < .001) with eribulin versus dacarbazine, respectively. Longer OS with eribulin was observed in all LPS histologic subtypes and in all geographic regions evaluated. PFS was also improved with eribulin versus dacarbazine (2.9 v 1.7 months, respectively; hazard ratio, 0.52; 95% CI, 0.35 to 0.78; P = .0015). Adverse events were similar between arms. Conclusion In patients with previously treated LPS, eribulin was associated with significantly superior OS and PFS compared with dacarbazine. Eribulin represents an important treatment option for patients with LPS, a sarcoma subtype for which limited effective systemic treatments are available. Further studies are justified to explore the role of eribulin in earlier lines of therapy as well as in combination with other agents.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Demetri GD, Schöffski P, Grignani G, et al. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017. PMID: 28854066. doi:10.1200/JCO.2016.71.6605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。